|Print This Page Email to a Friend|
Supported by funds from the Mayer Mitchell Award, Yaguang Xi, M.D., Ph.D., and his research team recently attended the American Association for Cancer Research Precision Medicine Series in Orlando, Fla., entitled “Cancer Cell Cycle-Tumor Progression and Therapeutic Response.”
Dr. Xi, associate professor of oncologic sciences at USA Mitchell Cancer Institute, was the 2015 recipient of the annual Mayer Mitchell Award for Excellence in Cancer Research, which awards $10,000 to be used for any research purpose other than salary enhancement.
At the meeting, Dr. Xi’s lab members presented five posters:
“Inhibition of breast cancer cell metastasis with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGFβ/miR-21 signaling” by Dr. Bin Yi.
“MiR-200 is involved in anti-invasive activity of sulindac in colon cancer” by Dr. Hong Chang.
“Sulindac inhibition of tumor cell transformation” by Dr. Zhipin Liang.
“Sulindac inhibition of colon tumor cell growth through miR-182/FOXO3a/CyclinG2 signaling” by Dr. Hongyou Zhao
“Oncogenic role of snoRD93 in breast cancer cells” by Dr. Ruixia Ma.
Dr. Ma’s study is part of a collaboration with Dr. Glen Borchert of the USA Department of Biology and supported by a Mitchell Cancer research grant. At the meeting, Dr. Xi’s team interacted with researchers from other countries, and discussed potential opportunities for collaboration in several projects.
The Mayer Mitchell Award was established in 2009 by USA Trustee Arlene Mitchell in memory of her husband, the late Mayer Mitchell, a Mobile businessman, philanthropist, longtime USA trustee and a formative figure in the establishment of MCI.
© 2017 USA Health System